ReviewBrain sciences2021
COVID-19 and Alzheimer's Disease.
Review in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Long COVID involves activation of proinflammatory and immune exhaustion pathways.Nature immunology · 2026Observational
- Burden and risk factors of Alzheimer's disease and other dementias in Vietnam from 1990 to 2021 - A comprehensive analysis from global burden disease.Cerebral circulation - cognition and behavior · 2025Article
- Neurological, psychological, psychosocial complications of long-COVID and their management.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Anti-inflammatory effects ofFrontiers in pharmacology · 2025Article
- Shared Genetic Architecture Between COVID-19 Severity and Alzheimer's Disease Across European and African Ancestries.Research square · 2024Article
- Lattice 123 pattern for automated Alzheimer's detection using EEG signal.Cognitive neurodynamics · 2024Article
- Molecular cross-talk between long COVID-19 and Alzheimer's disease.GeroScience · 2024Review
- COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?Metabolites · 2024Review
- Viral Infections, Are They a Trigger and Risk Factor of Alzheimer's Disease?Pathogens (Basel, Switzerland) · 2024Review
- Review
- Alzheimer's disease and infectious agents: a comprehensive review of pathogenic mechanisms and microRNA roles.Frontiers in neuroscience · 2024Review
- Human-derived air-liquid interface cultures decipher Alzheimer's disease-SARS-CoV-2 crosstalk in the olfactory mucosa.Journal of neuroinflammation · 2023Article
- The Evolution of Excess Deaths in the United States During the First 2 Years of the COVID-19 Pandemic.American journal of epidemiology · 2023Article
- Cognitive Aspects of COVID-19.Current neurology and neuroscience reports · 2023Review
- The Link Between COVID-19 and Alzheimer Disease Through Neuroinflammation.Clinical medicine & research · 2023Article
- Severe acute respiratory syndrome coronavirus 2 infection leads to Tau pathological signature in neurons.PNAS nexus · 2023Article
- Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies.Clinical and experimental medicine · 2023Article
- Alzheimer's disease risk after COVID-19: a view from the perspective of the infectious hypothesis of neurodegeneration.Neural regeneration research · 2023Review
- Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults.Scientific reports · 2023Observational
- Uncovering the Correlation between COVID-19 and Neurodegenerative Processes: Toward a New Approach Based on EEG Entropic Analysis.Bioengineering (Basel, Switzerland) · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a neurotropic virus with a high neuroinvasive potential. Indeed, more than one-third of patients develop neurological symptoms, including confusion, headache, and hypogeusia/ageusia. However, long-term neurological consequences have received little interest compared to respiratory, cardiovascular, and renal manifestations. Several mechanisms have been proposed to explain the potential SARS-CoV-2 neurological injury that could lead to the development of neurodegenerative diseases, including Alzheimer's Disease (AD). A mutualistic relationship between AD and COVID-19 seems to exist. On the one hand, COVID-19 patients seem to be more prone to developing AD. On the other hand, AD patients could be more susceptible to severe COVID-19. In this review, we sought to provide an overview on the relationship between AD and COVID-19, focusing on the potential role of biomarkers, which could represent precious tool for early identification of COVID-19 patients at high risk of developing AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.